依氟鸟氨酸(DFMO)用于尤文氏肉瘤和骨肉瘤
一项使用依氟鸟氨酸(DFMO)治疗尤文肉瘤和骨肉瘤的II期开放标签篮式试验研究
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:BCC Enroll
- 电话号码:7175310003
- 邮箱:BCCEnroll@pennstatehealth.psu.edu
学习地点
-
-
Florida
-
Tampa、Florida、美国、33614
- 招聘中
- St. Joseph's Children's Hospital
-
接触:
- Jennifer Manns
- 邮箱:jennifer.manns@baycare.org
-
首席研究员:
- Don Eslin
-
-
Oregon
-
Portland、Oregon、美国、97227
- 招聘中
- Randall Children's Hospital
-
接触:
- Aaron White
- 邮箱:AJWHITE@lhs.org
-
首席研究员:
- Jason Glover
-
-
Pennsylvania
-
Hershey、Pennsylvania、美国、17033
- 招聘中
- Penn State Milton S. Hershey Medical Center and Children's Hospital
-
首席研究员:
- Valerie Brown, MD
-
接触:
- Penn State Clinical Trials Group Email
- 邮箱:ExtractClinicalTrials@pennstatehealth.psu.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Cohort 1:
Inclusion Criteria:
-
Participants must be ≤50 years of age at enrollment.
-
Histologically confirmed Ewing sarcoma that is refractory or in first or subsequent relapse. Histological confirmation either at initial diagnosis or disease progression.
- Relapsed: Participants that have achieved CR at any point and then relapsed following/during standard of care therapy.
- Refractory: Participants that failed to achieve CR after standard of care therapy or having progressed during standard of care therapy.
- Note: Standard of care therapy for Ewing sarcoma includes multi-agent chemotherapy with local control consisting of either surgery and/or radiation therapy.
-
Extent of disease is judged by treating team to be amenable to the delivery of definitive local control (either definitive radiation, surgery, or a combination of these) at the time of study enrollment (to be completed after protocol defined Cycle 2).
-
Participants may enroll anytime during Cycle 1 or 2, prior to local control, as long as they received the same treatment during Cycle 1 and 2 as prescribed in this protocol.
-
Relapsed or refractory disease, including at least one of the following:
- Tumor by CT or MRI
- FDG-PET that is positive for disease
- Bone Marrow biopsy/aspirate that is positive for disease
Organ Function Requirements:
-
Participants must have adequate renal function as defined as:
- For participants < 17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Bedside Schwartz equation (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Bedside Schwartz equation is: [(0.413) X (Height in cm)] / SCr
- For participants ≥17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Cockcroft and Gault formula (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Cockcroft and Gault formula is: [(140-age) x (Wt in kg) x (0.85 if female)] / (72 x SCr)
- OR a 24 hour urine Creatinine clearance ≥ 70 mL/min/1.73 m2
-
Adequate liver function defined as:
- Total bilirubin ≤1.5 x upper limit of normal (ULN) for age, and
- SGPT (ALT <3 x upper limit of normal (ULN) for age (except for participants with liver metastasis who may enroll if ALT < 5 times ULN for age).
-
Adequate cardiac function defined as:
- Shortening fraction of ≥27% or
- Ejection fraction of ≥50%
-
Participants must have fully recovered from the hematological and bone marrow suppression effects of prior chemotherapy.
-
Participants must have a Lansky Play Scale or Karnofsky Performance Scale score of ≥ 60.
-
Participants of childbearing potential must have a negative pregnancy test and agree to use an effective birth control method. Participants who are lactating must agree to stop breast-feeding.
-
Written informed consent in accordance with institutional and FDA guidelines must be obtained from all participants (or participants' legal representative).
Exclusion Criteria:
- BSA of <0.25 m2
- Participants with current CNS disease.
- Investigational Drugs: Participants who are currently receiving another investigational drug are excluded from participation.
- Anti-cancer Agents: Participants who are currently receiving other anticancer agents are not eligible.
- Infection: Participants who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
- Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.
Cohort 2:
Inclusion Criteria:
-
Age
-
Participants must be ≤50 years of age at enrollment.
Note:
• Infants and small children are eligible for this study, however, the treating physicians and family must be prepared to deliver adequate local control as required in this study (see BCC Surgical and Imaging Guidelines).
Diagnosis
-
Participants with histologic diagnosis (by institutional pathologist) of newly diagnosed Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other metastatic site.
For the purpose of this study, metastatic disease is defined as one or more of the following:
-
Lesions which are discontinuous from the primary tumor, are not regional lymph nodes, and do not share a bone or body cavity with the primary tumor. Skip lesions in the same bone as the primary tumor do not constitute metastatic disease. Skip lesions in an adjacent bone are considered bone metastases. If there is any doubt whether lesions are metastatic, a biopsy of those lesions should be performed.
-
Contralateral pleural effusion and/or contralateral pleural nodules.
-
Distant lymph node involvement.
-
Participants with pulmonary nodules are considered to have metastatic disease if the participant has:
- Solitary nodule ≥0.5 cm or multiple nodules of ≥0.3 cm unless lesion is biopsied and negative for tumor;
- Participants with solitary nodule <0.5 cm or multiple nodules <0.3 cm are not considered to have lung metastasis unless biopsy documents tumor.
-
Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma based on H&E stains. In the absence of morphologic evidence of marrow involvement on H&E, participants with bone marrow involvement detected ONLY by flow cytometry, RT PCR, FISH, or immunohistochemistry will NOT be considered to have clinical bone marrow involvement for the purposes of this study.
For participants that have a positive FDG-PET scan at study enrollment, a bilateral bone marrow biopsy will be required at study entry. If a bone marrow is required, the suggested approach for participants with large pelvic tumors in which a posterior iliac crest bone marrow biopsy would track through the tumor is to instead undergo 2 marrow biopsies on the contralateral side (either 2 posterior biopsies or one posterior and one anterior biopsy).
• Bone metastasis: This study utilizes whole body FDG-PET scans to screen participants for bone metastases. Areas suspicious for bone metastasis based on FDG-PET scans require confirmatory anatomic imaging with either MRI or CT (whole body FDG-PET/CT or FDG-PET/MR scan acceptable). Whole body technetium bone scans may be performed at the discretion of the investigator and are not required. For participants without other sites of metastatic disease whose sole metastatic site to qualify for study entry is a single area suspicious for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic imaging evidence of an associated soft tissue mass at that site is required for study entry.
Prior Therapy
-
-
Participants must have completed 6 cycles of Induction therapy with VDC/IE per US standard of care (including standard modifications). Participants will enroll after the 6th cycle prior to local control.
Organ Function Requirements
-
Adequate renal function defined as:
- For participants < 17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Bedside Schwartz equation (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Bedside Schwartz equation is: [(0.413) X (Height in cm)] / SCr
- For participants ≥17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Cockcroft and Gault formula (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Cockcroft and Gault formula is: [(140-age) x (Wt in kg) x (0.85 if female)] / (72 x SCr)
- OR a 24 hour urine Creatinine clearance ≥ 70 mL/min/1.73 m2
-
Adequate liver function defined as:
- Total bilirubin ≤1.5 x upper limit of normal (ULN) for age, and
- SGPT (ALT <3 x upper limit of normal (ULN) for age (except for participants with liver metastasis who may enroll if ALT < 5 times ULN for age).
-
Adequate cardiac function defined as:
- Shortening fraction of ≥27% or
- Ejection fraction of ≥50%
-
Participants must have fully recovered from the hematological and bone marrow suppression effects of prior chemotherapy.
-
Participants must have a Lansky Play Scale or Karnofsky Performance Scale score of ≥ 60.
-
Participants of childbearing potential must have a negative pregnancy test and agree to use an effective birth control method. Participants who are lactating must agree to stop breast-feeding.
-
Written informed consent in accordance with institutional and FDA guidelines must be obtained from all participants (or participants' legal representative).
-
Exclusion Criteria:
- BSA of <0.25 m2
- Investigational Drugs: Participants who are currently receiving another investigational drug are excluded from participation.
- Anti-cancer Agents: Participants who are currently receiving other anticancer agents are not eligible.
- Participants with regional node involvement as their only site of disease beyond the primary tumor.
- Participants whose primary tumors arise in the intra-dural soft tissue (e.g. brain and spinal cord).
- Participants with current CNS disease
- Infection: Participants who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
- Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.
Cohort 3:
Inclusion Criteria:
-
Age
-
Participants must be less than 30 years of age at enrollment.
Diagnosis
-
Participants must have histologic diagnosis of osteosarcoma at original diagnosis.
-
Participants must have had at least one episode of disease recurrence in the lungs without limitation on number of episodes of recurrence as long as they meet the following criteria:
- Surgical resection of all possible sites of suspected pulmonary metastases in order to achieve a complete remission within 4 weeks prior to study enrollment*
- Pathologic confirmation of metastases from at least one of the resected sites.
- No local recurrence or metastatic disease elsewhere. *For participants with bilateral pulmonary metastases, resection must be performed from both lungs and the study enrollment must be within 4 weeks from date of the last lung surgery. No evidence of pulmonary metastatic disease; participants may have no visible lung nodules greater than 3 mm, and not considered to be disease.
Note: If surgery related changes such as atelectasis are seen on the post-operative CT scan, participants will remain eligible to enroll as long as the operating surgeon believes that all sites of metastases were resected. Participants with positive microscopic margins will be eligible to enroll.
Performance Level
-
Participants must have a Lansky Play Scale or Karnofsky Performance Scale score of ≥ 60.
Timing from Prior Therapy
-
Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
- Myelosuppressive anti-cancer therapy: Must not have been received within 2 weeks of study entry (4 weeks if prior nitrosourea).
- Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent.
- Radiation therapy (RT): ≥2 weeks for local palliative RT (small port); ≥6 weeks must have elapsed if prior craniospinal RT or if ≥50% radiation of pelvis; ≥6 weeks must have elapsed if other substantial BM radiation.
- Surgery: ≥2 weeks from last major surgery, including pulmonary metastasectomy, with the exclusion of a central line placement and core needle or small open biopsies.
Organ Function Requirements
-
Hematological:
- Platelet count ≥50,000/μL without transfusion in last 7 days
- Hgb ≥8.5 without transfusion in last 7 days
-
Adequate renal function defined as:
- For participants < 17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Bedside Schwartz equation (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Bedside Schwartz equation is: [(0.413) X (Height in cm)] / SCr
- For participants ≥17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Cockcroft and Gault formula (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Cockcroft and Gault formula is: [(140-age) x (Wt in kg) x (0.85 if female)] / (72 x SCr)
- OR a 24 hour urine Creatinine clearance ≥ 70 mL/min/1.73 m2
-
Adequate liver function defined as:
- Total bilirubin ≤1.5 x upper limit of normal (ULN) for age.
- SGPT (ALT <3 x upper limit of normal (ULN) for age.
-
Adequate cardiac function defined as:
- Shortening fraction of ≥27%, or
- Ejection fraction of ≥50%.
-
Adequate pulmonary function defined as:
o No evidence of dyspnea at rest, no history of exercise intolerance, and a pulse oximetry >94%.
-
Participants of childbearing potential must have a negative pregnancy test and agree to use an effective birth control method. Participants who are lactating must agree to stop breast-feeding.
-
Written informed consent in accordance with institutional and FDA guidelines must be obtained from all participants (or participants' legal representative).
-
Exclusion Criteria:
-
BSA of <0.25 m2
-
Investigational Drugs: Participants who are currently receiving another investigational drug are excluded from participation.
-
Anti-cancer Agents: Participants who are currently receiving other anticancer agents are not eligible.
-
Participants with distant bone metastases at original diagnosis or any subsequent relapse (participants with only skip lesions will be eligible).
-
Participants with concurrent local and pulmonary recurrence at the time of most recent episode of disease recurrence preceding enrollment.
Note: participants who had local recurrence previously that has been treated and then presented with an isolated pulmonary recurrence and met the surgical resection criteria stated above will be eligible (see IC #3 above).
-
Participants with primary refractory disease with progression of the primary tumor on initial therapy.
-
Participants with other sites of extra-pulmonary metastases at the time of any episode of disease recurrence preceding enrollment.
-
Infection: Participants who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
-
Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in who compliance is likely to be suboptimal.
Cohort 4A/B:
Inclusion Criteria:
Diagnosis Both Cohorts
-
Participants must have high grade osteosarcoma and received gross total resection prior to start of Cycle 3 MAP therapy. Participants with positive margins are eligible and may receive radiation therapy. This includes secondary malignancies.
o Note: craniofacial osteosarcoma is NOT permitted.
-
The primary tumor was resectable after the initial 2 cycles of MAP chemotherapy.
-
Participants must have had a non-contrast chest CT and primary tumor site imaging consisting of an MRI or CT for optimal visualization of primary tumor site prior to local control. Physical scans and scan reports must be available to submit to BCC.
Note: Two-view plain radiographs of the primary tumor site can be performed for participants who have a metallic prosthetic implant instead of CT or MRI if a significant metal artifact would occur by those imaging modalities;
Cohort A only
-
Participant must have poor response to induction chemotherapy (those with 10% or more viable tumor remaining after surgery) and localized tumor.
Cohort B only
-
Have an initial diagnosis of high-grade metastatic extremity or axial osteosarcoma resectable by the treating team.
o Note: Metastatic pulmonary disease is defined as 3 or more lesions >5 mm or 1 lesion >1 cm or biopsy proven pulmonary metastatic disease if not meeting these radiographic criteria;
-
No definite progression of metastatic disease and no evidence of new metastatic disease.
-
Following definitive primary surgery, complete removal of all metastases or complete removal planned and deemed feasible.
Non-Diagnostic Inclusion Criteria, Both Cohorts Age
-
Participants must be ≥5 years and ≤40 years on date of diagnostic biopsy. Performance Level
-
Participants must have a Lansky Play Scale or Karnofsky Performance Scale score of ≥ 60. Participants whose performance status is adversely affected by a pathologic fracture but who are able to undergo treatment are eligible.
Prior Therapy
-
Participants must have completed standard induction therapy for initial diagnosis osteosarcoma (2 cycles [10weeks]) of MAP, Local control (surgery, assessment of histologic response), and a post-surgery 3rd cycle (5 weeks) of MAP. Participants will enroll after the 3rd cycle of MAP.
Organ Function Requirements
-
Participants must have adequate renal function defined:
- For participants < 17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Bedside Schwartz equation (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Bedside Schwartz equation is: [(0.413) X (Height in cm)] / SCr
- For participants ≥17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Cockcroft and Gault formula (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Cockcroft and Gault formula is: [(140-age) x (Wt in kg) x (0.85 if female)] / (72 x SCr)
- OR a 24 hour urine Creatinine clearance ≥ 70 mL/min/1.73 m2
-
Adequate cardiac function defined as:
- Shortening fraction of ≥28%, or
- Ejection fraction of ≥50%
-
Adequate liver function defined as:
- Total bilirubin ≤1.5 x upper limit of normal (ULN) for age
- SGPT (ALT <3 x upper limit of normal (ULN) for age.
-
Participants must have fully recovered from the hematological and bone marrow suppression effects of prior chemotherapy.
-
Participants of childbearing potential must have a negative pregnancy test and agree to use an effective birth control method. Participants who are lactating must agree to stop breast-feeding.
-
Written informed consent in accordance with institutional and FDA guidelines must be obtained from all participants (or participants' legal representative).
Exclusion Criteria:
- BSA of <0.25 m2
- Investigational Drugs: Participants who are currently receiving another investigational drug are excluded from participation.
- Anti-cancer Agents: Participants who are currently receiving other anticancer agents are not eligible.
- Infection: Participants who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
- Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in who compliance is likely to be suboptimal.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort 1: Relapsed or Refractory Ewing Sarcoma Eligible to Receive Local Control
DFMO will be administered as concurrent therapy during treatment of Ewing sarcoma. Participants completing treatment without experiencing an analytic event will continue to receive DFMO monotherapy as a maintenance treatment for an additional 24 months. |
IV Oral twice daily
其他名称:
IV |
|
实验性的:Cohort 2: Ewing Sarcoma Patients who are Metastatic at Diagnosis
DFMO will be administered as concurrent therapy during consolidation treatment of metastatic Ewing sarcoma. Participants completing consolidation treatment without experiencing an analytic event will continue to receive DFMO monotherapy as a post consolidation maintenance treatment for an additional 24 months. |
IV IV IV Oral twice daily
其他名称:
IV IV |
|
实验性的:Cohort 3: Osteosarcoma with relapse in the lung after resection of lung metastases
DFMO will be dosed twice daily for 730 days. |
Oral twice daily
其他名称:
|
|
实验性的:Cohort 4A: Osteosarcoma with Poor Response to Induction Therapy at Completion of Local Control
DFMO will be administered as concurrent therapy during Cycles 4-6 of post-surgery consolidation. Participants completing MAP without experiencing an analytic event will continue to receive DFMO monotherapy as a post consolidation maintenance treatment for an additional 24 months. |
IV IV Oral twice daily
其他名称:
IV |
|
实验性的:Cohort 4B: Osteosarcoma with Metastatic Disease at Diagnosis at Completion of Local Control
DFMO will be administered as concurrent therapy during Cycles 4-6 of post-surgery consolidation. Participants completing MAP without experiencing an analytic event will continue to receive DFMO monotherapy as a post consolidation maintenance treatment for an additional 24 months. |
IV IV Oral twice daily
其他名称:
IV |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Cohort 1 participants with relapse free survival (RFS) during study
大体时间:2 years plus 5 years follow up
|
Cohort 1: To determine if relapse-free survival (RFS) in participants with relapsed or refractory Ewing sarcoma treated with multiagent chemotherapy is improved with the addition of DFMO as compared to historical outcomes of participants treated with the same multiagent chemotherapy without DFMO. |
2 years plus 5 years follow up
|
|
Number of Cohort 2 participants with event-free survival (EFS) during study
大体时间:2 years plus 5 years follow up
|
Cohort 2: To determine if event-free survival (EFS) in participants with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy is improved with the addition of DFMO as compared to historical outcomes of participants treated with the same multiagent chemotherapy without DFMO. |
2 years plus 5 years follow up
|
|
Cohort 3: Number of Cohort 3 participants at 12 months with disease control
大体时间:1 year plus 5 years follow up
|
To determine the 12-month disease control rate (DCR) in participants with completely resected recurrent osteosarcoma treated with DFMO as compared to historical controls. |
1 year plus 5 years follow up
|
|
Cohort 4A: Number of Cohort 4A participants with event-free survival (EFS) during study
大体时间:2 years plus 5 years follow up
|
Examine whether the addition of DFMO to post-operative chemotherapy with cisplatin, doxorubicin, and methotrexate (MAP) improves the event-free survival (EFS) for participants with osteosarcoma having localized disease with a poor histological response to 10 weeks of pre-operative chemotherapy. |
2 years plus 5 years follow up
|
|
Cohort 4B: Number of Cohort 4B participants with event-free survival (EFS) during study
大体时间:2 years plus 5 years follow up
|
Examine whether the addition of DFMO to post-operative chemotherapy with cisplatin, doxorubicin, and methotrexate (MAP) improves the event-free survival (EFS) for participants with osteosarcoma with metastatic disease at diagnosis (Cohort 4B). |
2 years plus 5 years follow up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Length of time that participants experience Overall Survival (OS)
大体时间:10 Years
|
To compare overall survival in DFMO-treated participants versus historical controls. |
10 Years
|
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
大体时间:2 years
|
To characterize safety and tolerability of DFMO plus multiagent chemotherapy. |
2 years
|
合作者和调查者
调查人员
- 学习椅:Giselle SaulnierSholler, MD、Penn State Health Children's Hospital
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 肿瘤
- 组织学类型的肿瘤
- 肉瘤
- 肿瘤、结缔组织和软组织
- 肿瘤,骨组织
- 肿瘤,结缔组织
- 肉瘤,尤因
- 骨肉瘤
- 氨基酸,肽和蛋白质
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- Camptothecin
- 生物碱
- Podophyllotoxin
- 四氢乙烯甲烯烃
- 萘
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 葡萄糖剂
- 糖苷
- 吲哚
- 无机化学物质
- 氯化合物
- 氮化合物
- 氨基酸
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 翼
- 翼状
- VINCA生物碱
- Secologanin色素生物碱
- 吲哚生物碱
- 吲哚衍生物
- 吲哚王
- 氨基翅目
- 蒽环类动物
- 萘烯
- 氨基糖苷
- 白金化合物
- 氨基酸,碱性
- 氨基酸,Diamino
- Daunorubicin
- 奥沙嗪
- 鸟氨酸
- 甲氨蝶呤
- 环磷酰胺
- 依托泊苷
- 阿霉素
- 长春新碱
- 顺铂
- 拓扑替康
- 异环磷酰胺
- 依氟鸟氨酸
其他研究编号
- BCC023
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.